CD4 and neoplasm: In the future it will be worth examining in tumor-bearing humanized mice whether blocking CCL18 or PITPNM3 also leads to enhanced anti-tumor immunity and tumor suppression, and to compare it with anti-CCR8 and with CD4-AsiCs against PITPNM3 or CCR8. In this study, CD4-AsiCs against PITPNM3 did not affect PB T cell subset numbers or lead to any apparent toxicity in humanized mice.